Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-08-2019 | NSCLC | Original Article – Clinical Oncology

A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy

Authors: Han Han, Yue Zhao, Zhendong Gao, Difan Zheng, Fangqiu Fu, Zitong Zhao, Ya Tang, Jiaqing Xiang, Yihua Sun, Hong Hu, Haiquan Chen

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2019

Abstract

Purpose

The survival of patients with IIIA-N2 non-small cell lung cancer after surgery followed by adjuvant chemotherapy is heterogeneous. The aim of this study is to form a prognostic system and a heat map method to visualize the overall survival rates in those patients.

Methods

Univariate and multivariate Cox hazards regression models and the associated Wald Chi square coefficient were used to form the prognostic score system. Recursive partitioning analysis was used to determine the cutoff values of lymph node ratio and prognostic score in SEER cohort and validated in FDUSCC cohort. Meanwhile, a heat map method was used to visualize the overall survival probabilities of 3, 5 and 10 years for individual patient of both cohorts.

Results

Lymph node ratio (with cutoff of 0.36) significantly correlates with overall survival of these patients. In addition, in patients with the same level of N2 disease, lymph node ratio still significantly affects survival. Also, after the multivariate analysis in SEER cohort, six factors were independent prognostic factors including age, sex, type of surgery, size, lymph node ratio and differentiation. A prognostic sore system with these factors (with cutoff of 12) was validated as a predictor for overall survival in FDUSCC cohort.

Conclusions

This prognostic score system including lymph node ratio can predict the survival rates of IIIA-N2 patient after surgery and post-operative chemotherapy. Lymph node ratio could be a useful supplementation in TNM stage classification for IIIA-N2 patients. The heat map method can visualize the predicted overall survival of an individual patient.

Arriagada R et al (2010) Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet (London, England) 375:1267–1277. https://doi.org/10.1016/s0140-6736(10)60059-1 CrossRef

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492 CrossRef

Deng W et al (2018) Survival patterns for patients with resected N2 Non-small cell lung cancer and postoperative radiotherapy: a prognostic scoring model and heat map approach. J Thorac Oncol 13:1968–1974. https://doi.org/10.1016/j.jtho.2018.08.2021 CrossRefPubMed

Goldstraw P et al (2016) The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51. https://doi.org/10.1016/j.jtho.2015.09.009 CrossRef

Keles S, Segal MR (2002) Residual-based tree-structured survival analysis. Stat Med 21:313–326CrossRefPubMed

Liu S et al. (2016) Precise diagnosis of intraoperative frozen section is an effective method to guide resection strategy for peripheral small-sized lung adenocarcinoma. J Clin Oncol 34:307–313 https://doi.org/10.1200/jco.2015.63.4907. https://doi.org/10.1200/jco.2016.34.2_suppl.307

Nwogu CE et al (2012) Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Ann Thorac Surg 93:1614–1619. https://doi.org/10.1016/j.athoracsur.2012.01.065 (discussion 1619–1620) CrossRefPubMedPubMedCentral

Postmus PE et al (2017) Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv1–iv21. https://doi.org/10.1093/annonc/mdx222 CrossRefPubMed

Qiu C, Dong W, Su B, Liu Q, Du J (2013) The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer. J Thorac Oncol 8:429–435. https://doi.org/10.1097/JTO.0b013e3182829c16 CrossRefPubMed

Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P (2009) The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 4:568–577. https://doi.org/10.1097/JTO.0b013e3181a0d82e CrossRef

Taylor MD et al (2013) Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer. Ann Thorac Surg 96:1163–1170. https://doi.org/10.1016/j.athoracsur.2013.04.031 CrossRefPubMed

Urban D, Bar J, Solomon B, Ball D (2013) Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer. J Thorac Oncol 8:940–946. https://doi.org/10.1097/JTO.0b013e318292c53e CrossRefPubMed

Wong VW et al (2010) Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 28:1660–1665. https://doi.org/10.1200/jco.2009.26.2675 CrossRef

Xi M et al (2017) A prognostic scoring model for the utility of induction chemotherapy prior to neoadjuvant chemoradiotherapy in esophageal cancer. J Thorac Oncol 12:1001–1010. https://doi.org/10.1016/j.jtho.2017.03.017 CrossRefPubMed

Zhao Y, Li G, Zheng D, Jia M, Dai W, Sun Y, Chen H (2017) The prognostic value of lymph node ratio and log odds of positive lymph nodes in patients with lung adenocarcinoma. J Thorac Cardiovasc Surg 153:702–709.e701. https://doi.org/10.1016/j.jtcvs.2016.11.053 CrossRefPubMed

Zheng D, Ye T, Hu H, Zhang Y, Sun Y, Xiang J, Chen H (2018) Upfront surgery as first-line therapy in selected patients with stage IIIA non-small cell lung cancer. J Thorac Cardiovasc Surg 155:1814–1822.e1814. https://doi.org/10.1016/j.jtcvs.2017.10.075 CrossRefPubMed

Title: A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy
Authors: Han Han
Yue Zhao
Zhendong Gao
Difan Zheng
Fangqiu Fu
Zitong Zhao
Ya Tang
Jiaqing Xiang
Yihua Sun
Hong Hu
Haiquan Chen
Publication date: 01-08-2019
Publisher: Springer Berlin Heidelberg
Keywords: NSCLC
NSCLC
Cytostatic Therapy
Published in: Journal of Cancer Research and Clinical Oncology / Issue 8/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-02952-w

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2019

Effect of age on the effectiveness of the first-line standard of care treatment in patients with metastatic colorectal cancer: systematic review of observational studies

Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer

Human cytomegalovirus infection is correlated with enhanced cyclooxygenase-2 and 5-lipoxygenase protein expression in breast cancer

Kaplan–Meier analysis of salivary gland tumors: prognosis and long-term survival

Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer

Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page